Archive | Hot Mandates RSS feed for this section

Hot Investor Mandate: USA-Based Private Investment Firm Seeks Early-Stage Digital Health Companies that Address Lower Costs and Enhance Quality of Care

22 Jul

A private investment firm based in the USA started a fund to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The firm focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Corporate Venture Arm of Global Company Makes Strategic Investments in Companies Dedicated to Human Nutritional Health

22 Jul

The corporate venture capital arm of a global science-based company active in health, nutrition and materials makes equity investments into seed and venture stage companies generally taking less than 25% ownership. The firm makes allocations ranging from a few hundred thousand dollars to $5 million initially with additional capital held for future financing rounds. The firm is looking to make approximately 5-10 investments over the next 6-9 months with +10 being made over the next 2 years. The firm invests in companies located around the globe with a focus on the U.S., Europe and Israel.

The firm is looking for materials science companies in orthopedics and soft tissue repair. The firm also actively invests in human nutritional health, with a specific focus on companies active in personalized nutrition, and companies developing nutritional products. While the firm has invested in companies all the way from seed to PIPE, they generally invest into companies that have products in development or early stage commercialization.

The firm highly values experience in a firms management team and generally looks to take a board seat and play an active role in its portfolio companies. The firm is looking for companies that are interested in cooperation/alignment with relevant businesses of the parent company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Korean Pharmaceutical Company Seeks Global, Novel Therapeutic Candidates in CNS, Immunology, Liver Diseases, and More

22 Jul

A pharmaceutical company based in South Korea has an active portfolio that is mostly made of branded products licensed in from overseas partners. For the R&D activity, the firm has several clinical pipelines under global phase II in the area of CNS and diabetes, CNS clinical pipeline under phase III in Korea, and a late preclinical stage oncology product as well as an early preclinical candidates targeting TEC kinase family developed in-house. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline and product portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. In terms of indications, the firm is indication agnostic with added interest in movement disorders, CNS, liver disease and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in early/late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Longevity Mandate: New York-Based Family Office

20 Jul

The firm is a private investment firm based in New York, NY. The firm launched the Health Tech Fund in 2012 to invest in early stage companies that are developing innovations that can significantly reduce healthcare costs. The firm makes equity investments where the investment size is highly variable depending on the stage of development and particular need of each company. The firm invests in companies that are based in the US and is actively seeking new investment opportunities.

The Health Tech Fund focuses on early-stage healthcare IT projects that could substantially lower the cost of healthcare delivery in the United States. Examples of good candidates include projects that help consumers make more informed decisions when selecting local service providers (cost transparency); use remote monitoring technology to help patients better manage illness; that provide more meaningful tracking of health metrics for patients (health and wellness analytics); or initiatives at the intersection of molecular diagnostics and bioinformatics that comb genetic blueprints for clinically-relevant patterns (precision medicine).

The firm is an active and engaged investor, and can act as either a lead or co-investor. The firm prefers to lead investments in seed rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: Japanese Corporate Venture Capital Fund

20 Jul

The firm is a Japanese technology-based distributor and service solution provider of electronic components, enterprise IT and innovative solutions. Headquartered in Japan, the company operates 85 offices worldwide. The firm’s main business domains lie in semiconductors, IoT and cybersecurity, but seeks to expand beyond these realms to create new businesses, including healthcare, life sciences. The firm has been making strategic investments periodically to make business partnership with external technology startups from all around the world that align with the firm’s interests. The firm’s investment is stage agnostic but mostly between Seed and Series B financing rounds. The firm is open to business partnership and global investment opportunities from any country.

Within life sciences and healthcare, the firm is open to opportunities in digital therapeutics, devices, and digital health. Within therapeutics, the firm is primarily seeking enabling technologies in chronic diseases as diabetes, sleep disorders, mental health, and also depression and dementia. The firm will generally not consider opportunities such as pre-clinical antibody or small molecule assets that require a long window. The firm is also interested in devices (open to both 510k and PMA) or digital health technologies that are in the fields of primary care, elderly care, and mental health. Some examples of The firm’s investments include a continuous glucose monitoring device, an AI-driven robotics platform for chronic care management, and a digital therapeutics app for chronic diseases. While the firm can invest in very early-stage companies, the firm prefers to invest in companies with a viable product that is ready to be tested in pilots or clinical trials at the earliest. The firm does not

expect companies to have already received FDA approval and will help companies go through the regulatory process. Furthermore, the firm has an ongoing strategic partnership with the Japanese Organization for Medical Device Development (JOMDD), through which the firm helps companies with PMDA approval in Japan.

The firm has no specific company or management team requirements, and prefers to act as a co-investor. The firm does not require or seek board representation. As a completely strategic investor, the firm seeks to invest in companies that align with the firm’s new business goals and those that the firm can provide a strong value-add.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot Longevity Mandate: UK-Based Venture Capital Fund

20 Jul

The firm is a 60M Euro early-stage VC based in London. The firm invests broadly across deep tech including in healthcare and life-sciences. The team is looking for teams that are working on new and innovative technologies, the more unusual the better. The firm invests 1-2M EUR as a Seed+ round (between Seed and Series-A), often helping to bridge the gap between those rounds. The firm invests primarily in Europe, but will consider investing in companies based outside of Europe if they have a strong European connection.

The firm will consider technologies in all areas of healthcare, including therapeutics, diagnostics, drug delivery, tools, digital health and medical devices, instead focusing on the type of technology and how unique it is. They do not invest in single-asset therapeutic companies or repurposed assets. While open to all indications, the firm prefers to invest in underserved indications, such as neuroscience, infectious diseases, solid tumors, ophthalmology, and dermatology.

The firm can lead or follow in their investments. While they may take a board seat, they will only do so if it will be beneficial to the company. The firm invests in strong management teams including founder-driven companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.

Hot AI Mandate: US-based Family Office Invests In Medical Devices, Diagnostics & AI-related Digital Health

20 Jul

A family office based in New York, NY is looking to invest in medical devices and diagnostics, but will also consider therapeutics and digital health. The firm prefers companies that have some proof of concept data, with some animal studies complete, and will invest through to clinical-stage companies. The firm generally co-invests in a syndicate, and will invest between $100-500K, depending on the stage of development of the company. The firm is currently interested in investing in companies located in North America.

The firm is focused primarily on medical devices and diagnostics, but will consider therapeutics, if they are first in class, and digital health, with a focus on AI-related technologies. The firm has focused on technologies related to oncology, diabetes and kidney diseases, but will consider other indications as well.

The firm is interested in companies with strong management teams. As the firm will generally co-invest, board representation is not usually required after investing.

If you are interested in more information about this investor and other investors tracked by LSN, please email resi@lifesciencenation.com.

%d bloggers like this: